Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 10/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 12/20 | 0.88 |
| ▸ | FGFR3 | P22607 | 6/20 | 0.88 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.84 |
| ▸ | KDR | P35968 | 4/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21056242 | 1.00 | FGFR4 (1.00) | FGFR4FGFR2FGFR3FGFR1KDR | |
| SCHEMBL21050830 | 1.00 | FGFR4 (1.00) | FGFR4FGFR2FGFR3FGFR1KDR | |
| SCHEMBL21050893 | 0.94 | FGFR2 (1.00) | FGFR4FGFR2FGFR3FGFR1KDR | |
| SCHEMBL21050890 | 0.94 | FGFR2 (1.00) | FGFR4FGFR2FGFR3FGFR1KDR | |
| SCHEMBL21050832 | 0.91 | FGFR4 (1.00) | FGFR4FGFR2FGFR3FGFR1KDR | |
| SCHEMBL21056236 | 0.91 | FGFR4 (1.00) | FGFR4FGFR2FGFR3FGFR1KDR | |
| SCHEMBL21050780 | 0.91 | FGFR4 (1.00) | FGFR4FGFR2FGFR3FGFR1KDR | |
| SCHEMBL21091076 | 0.90 | FGFR4 (0.82) | FGFR4FGFR2FGFR3FGFR1KDR | |
| SCHEMBL21091078 | 0.90 | FGFR4 (0.82) | FGFR4FGFR2FGFR3FGFR1KDR | |
| SCHEMBL21091077 | 0.90 | FGFR4 (0.82) | FGFR4FGFR2FGFR3FGFR1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109715626-B | Heterocyclic compounds as FGFR inhibitors | 广州诺诚健华医药科技有限公司 | 2022-04-26 | — | — | CN | disclosed |
| US-10752631-B2 | Heterocyclic compounds as FGFR inhibitors | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2020-08-25 | — | — | US | disclosed |
| US-10752631-B2 | Heterocyclic compounds as FGFR inhibitors | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2020-08-25 | — | — | US | disclosed |
| EP-3498706-A1 | HETEROCYCLIC COMPOUND AS FGFR INHIBITOR | Guangzhou InnoCare Pharma Tech Co., Ltd. (CN) | 2019-06-19 | — | — | EP | disclosed |
| EP-3498706-A1 | HETEROCYCLIC COMPOUND AS FGFR INHIBITOR | Guangzhou InnoCare Pharma Tech Co., Ltd. (CN) | 2019-06-19 | — | — | EP | disclosed |
| US-20190177333-A1 | HETEROCYCLIC COMPOUNDS AS FGFR INHIBITOR | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-06-13 | — | — | US | disclosed |
| US-20190177333-A1 | HETEROCYCLIC COMPOUNDS AS FGFR INHIBITOR | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177333-A1 | HETEROCYCLIC COMPOUNDS AS FGFR INHIBITOR | FGFR1, FGFR3, FGFR2 | FGFR4 4/4885FGFR2 3/4885FGFR3 2/4885 |
| US-10752631-B2 | Heterocyclic compounds as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | FGFR4 4/4885FGFR2 3/4885FGFR3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.